Top Markets
#1 NKN NKN +163.44%
#2 Bluwhale Bluwhale +34.86%
#3 Codatta Codatta +29.93%
#4 SAFEcoin SAFEcoin +28.49%
#5 Saakuru Saakuru +24.27%
#6 StakeStone StakeStone +19.47%
#7 Yooldo Games Yooldo Games +16.45%
#8 Particle Network Particle Network +16.23%
#9 TronBank TronBank +13.65%
#10 Arcblock Arcblock +13.56%
Coin of the day
NKN NKN
設定
言語
日本
通貨
USD
テーマ
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
株式のランク #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
株価
$0.15
時価総額
$4.96M
変化（1日）
0.00%
変化（1年）
0.00%
国
CA
取引 Intellipharmaceutics International Inc. (IPCIF)

カテゴリー

Healthcare
Intellipharmaceutics International Inc.（IPCIF）の発行済株式数
August 2023 時点の発行済株式数 33.09M
Intellipharmaceutics International Inc. の最新の財務報告および株価によると、現在の発行済株式数は 33.09M です。November 2021 の終わりには、同社は 29.43M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Intellipharmaceutics International Inc.（IPCIF）の発行済株式数の履歴（1999 ～ 2026）
各年末時点の発行済株式数
年 発行済株式数 変化
2026 (TTM) 33.09M 0.00%
2022 33.09M 12.45%
2021 29.43M 24.90%
2020 23.56M 9.18%
2019 21.58M 353.15%
2018 4.76M 53.55%
2017 3.10M 16.16%
2016 2.67M 12.34%
2015 2.38M 3.11%
2014 2.31M 17.18%
2013 1.97M 13.98%
2012 1.73M 15.10%
2011 1.50M 37.47%
2010 1.09M -51.30%
2008 2.24M 13.63%
2007 1.97M 124.16%
2006 879.29K 10.85%
2005 793.22K 15.41%
2004 687.29K 11.69%
2003 615.38K 27.29%
2002 483.46K 7.69%
2001 448.93K 2.77%
2000 436.82K 49.40%
1999 292.38K 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数 差 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 13,340.60%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 667.24%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M 210.95%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M 474.14%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M 85.60%
NL